UC Berkeley's genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.
4D Molecular Therapeutics (4DMT), the US-based gene therapy spinout of University of California, Berkeley and backed by its Berkeley Catalyst Fund, withdrew its application for an initial public offering on Tuesday.
Founded in 2013, 4DMT is working on adeno-associated virus-based treatments for a genetic disorder known as Fabry disease, in addition to retinal conditions retinitis pigmentosa and choroideremia, and cystic fibrosis-related lung disease.
The company filed for a $100m IPO in September 2019 but had not…
